India, Oct. 18 -- Cancer treatment in India could become more affordable from November 9, as the National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% on 137 non-scheduled anti-cancer drug formulations. The move is expected to reduce retail prices by up to 70%, depending on the existing price structure of individual medicines.

The decision aims to reduce excessive mark-ups across the medicine supply chain and provide financial relief to patients and their families. But how does this new measure compare with the earlier price-control initiative, and will every cancer medicine become cheaper? Here is what patients need to know.

Cancer Drug Price Cut From November 9: What Has Changed?

The NPPA has introduced the...